ProCE Banner Activity

An Expert’s Guide to ASH 2023: Preview of the Top Abstracts

Conference Coverage
Clinical Thought

Experts highlight key studies being presented at the upcoming 2023 ASH Annual Meeting and Exposition. CCO’s Independent Conference Coverage will include timely summaries, expert analysis, and practical implications of the latest research and developments in hematology to help you stay at the forefront of advances in cancer care.

Released: December 07, 2023

Share

Faculty

Catherine M. Broome

Catherine M. Broome, MD

Professor of Medicine
Division of Hematology/Oncology
MedStar Georgetown University Hospital
Washington, DC

Ian Flinn

Ian Flinn, MD, PhD

Chief Scientific Officer
OneOncology
Nashville, Tennessee

Sagar Lonial

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Brady L. Stein

Brady L. Stein, MD, MHS

Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Eunice S. Wang

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.

Disclosure

Primary Author

Catherine M. Broome, MD

Professor of Medicine
Division of Hematology/Oncology
MedStar Georgetown University Hospital
Washington, DC

Catherine Broome, MD: consultant/advisor/speaker: Alexion, Argenx, Incyte, Sanofi; researcher: Alpine, Rigel, Star Therapeutics.

Ian Flinn, MD, PhD

Chief Scientific Officer
OneOncology
Nashville, Tennessee

Ian Flinn, MD, PhD: consultant: AbbVie, BeiGene, Genentech, Genmab, Kite, Vincerx; advisor: Vincerx; researcher (paid to institution): 2seventy bio, AbbVie, Acerta Pharma, Agios, ArQule, AstraZeneca, BeiGene, Biopath, Bristol Myers Squibb, Calibr-Skaggs Institute, Celgene, Constellation, Curis, CTI Biopharma, Epizyme, Fate Therapeutics, Forma Therapeutics, Forty Seven, Genentech, Gilead, InnoCare Pharma, IGM Biosciences, Incyte, Infinity, Janssen, Kite Pharma, Loxo, Marker Therapeutics, Merck, Millennium, MorphoSys, Myeloid Therapeutics, Novartis, Nurix, Pfizer, Pharmacyclics, Portola, Rhizen, Roche, Seattle Genetics, Step Pharma, Tessa Therapeutics, TG Therapeutics, Trillium Therapeutics, TRIPhase Research & Development, Unum Therapeutics, Verastem, Vincerx.

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD: consultant/advisor/speaker: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Janssen, Novartis, Pfizer, Regeneron, Takeda; independent contractor: TG Therapeutics.

Brady L. Stein, MD, MHS

Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Brady L. Stein, MD, MHS, has no relevant financial relationships to disclose. 

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Eunice S. Wang, MD: consultant/advisor/speaker: AbbVie, Blueprint, Bristol Myers Squibb, CTI Biopharma, Daiichi Sankyo, Gilead, GlaxoSmithKline, Immunogen, Johnson & Johnson, Kite, Kura, Novartis, Qiagen, Rigel, Schrodinger, Sellas, Stemline, Sumitomo, Syndax.